AbbVie Announces Positive Topline Results from Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata

AbbVie Announces Positive Topline Results from Phase 3 UP-AA Trial Evaluating Upadacitinib (RINVOQ®) for Alopecia Areata

In Study 2 of the pivotal Phase 3 UP-AA clinical program, upadacitinib (RINVOQ®) achieved the primary endpoint, demonstrating that 44.6% and 54.3% of patients...

Phase 3 Trial Finds Upadacitinib Promotes Significant Hair Regrowth in Alopecia Areata

Data show 44.6% and 54.3% of patients reached 80% or greater hair coverage with 15 mg and 30 mg doses, respectively. AbbVie announced positive topline results from the first of two pivotal studies of the phase 3 UP-AA clinical program evaluating the safety and efficacy of upadacitinib (Rinvoq; 15 mg and 30 mg, once daily) in adult and adolescent patients with severe alopecia areata with a mean baseline SALT score of 83.8 (approximately 16% scalp…

Alopecia areata data: Upadacitinib demonstrates improvements in scalp hair coverage

Achieving the primary endpoint, 44.6% and 54.3% of patients treated with upadacitinib (15 mg and 30 mg) reached 80% or more scalp hair coverage.

New Phase 3 UP-AA Data Demonstrate Significant Improvement in SALT Score With Upadacitinib in Alopecia

AbbVie's upadacitinib showed promising results in treating severe alopecia areata, achieving significant hair regrowth in pivotal phase 3 trials.